Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.

Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB; AACTG 266 Team.

Antiviral Res. 2004 Nov;64(2):103-11.

PMID:
15498605
3.

HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial.

Jabs DA, Gilpin AM, Min YI, Erice A, Kempen JH, Quinn TC; Studies of Ocular Complications of AIDS Research Group.

AIDS. 2002 Apr 12;16(6):877-87.

PMID:
11919489
6.
10.

Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994.

Wutoh AK, Hidalgo J, Rhee W, Bareta J, Steidl S.

Am J Health Syst Pharm. 1999 Jul 1;56(13):1314-8.

PMID:
10683128
11.

Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis.

Jabs DA, Martin BK, Forman MS, Hubbard L, Dunn JP, Kempen JH, Davis JL, Weinberg DV; Cytomegalovirus Retinitis and Viral Resistance Study Group.

Am J Ophthalmol. 2003 Jan;135(1):26-34.

PMID:
12504693
13.

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.

Biol Blood Marrow Transplant. 2001;7(6):343-51.

14.

Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival.

Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, Davey C, Johnson M, Emery V.

AIDS. 1996 Nov;10(13):1515-20.

PMID:
8931786
16.

High dose oral ganciclovir treatment for cytomegalovirus retinitis.

Lalezari JP, Friedberg DN, Bissett J, Giordano MF, Hardy WD, Drew WL, Hubbard LD, Buhles WC, Stempien MJ, Georgiou P, Jung DT, Robinson CA; Roche Cooperative Oral Ganciclovir Study Group.

J Clin Virol. 2002 Feb;24(1-2):67-77.

PMID:
11744430
17.

Evaluation of cytomegalovirus retinitis management. Outcome of four years of cytomegalovirus therapy.

Ries E, Mühlbauer B, Ruhswurm I, Krepler K, Derbolav A, Svolba G, Rieger A, Wedrich A.

Ophthalmologica. 1998;212(4):239-43.

PMID:
9672212
18.

Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.

Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C.

J Infect Dis. 1994 Jul;170(1):189-93.

PMID:
8014496
19.

Cytomegalovirus optic neuritis: characteristics, therapy and survival.

Mansor AM, Li HK.

Ophthalmologica. 1995;209(5):260-6.

PMID:
8570149
20.

High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.

Velez G, Roy CE, Whitcup SM, Chan CC, Robinson MR.

Am J Ophthalmol. 2001 Mar;131(3):396-7.

PMID:
11239885

Supplemental Content

Support Center